Adnexus Therapeutics, Inc.: Considering the Exit

Posted: 21 May 2009

See all articles by Vicki Sato

Vicki Sato

Harvard University

Rachel Gordon

Harvard University - Business School (HBS)

Date Written: November 11, 2008

Abstract

Dr. John Mendlein, CEO of Adnexus Therapeutics Inc., (Adnexus), a private biotechnology company, must decide whether to pursue acquisition talks with Bristol-Myers Squibb (BMS) after a successful six month collaboration or continue with Adnexus' planned IPO.

Suggested Citation

Sato, Vicki and Gordon, Rachel, Adnexus Therapeutics, Inc.: Considering the Exit (November 11, 2008). HBS Case No. 609-015; Harvard Business School Technology & Operations Mgt. Unit Paper No. 1408110. Available at SSRN: https://ssrn.com/abstract=1408110

Vicki Sato (Contact Author)

Harvard University ( email )

1875 Cambridge Street
Cambridge, MA 02138
United States

Rachel Gordon

Harvard University - Business School (HBS) ( email )

Soldiers Field Road
Morgan 270C
Boston, MA 02163
United States

Here is the Coronavirus
related research on SSRN

Paper statistics

Abstract Views
552
PlumX Metrics